We're off to the races!

Biogen Idec Submits Application to FDA for First Long-Lasting Factor IX Therapy For Hemophilia B

WESTON, Mass.– Today, Biogen Idec announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B. rFIXFc is the first product candidate in a new class of long-lasting clotting factor therapies that […]

en_USEnglish